News & Updates

For patients with advanced nonsmall cell lung cancer (NSCLC) who remain progression-free on immune checkpoint inhibitor (ICI)-based therapy at 2 years, continuing treatment does not appear to confer any survival advantage as opposed to stopping, according to a retrospective study presented at ASCO 2023.

In individuals with resectable non-small-cell lung cancer (NSCLC), the addition of perioperative durvalumab to neoadjuvant chemotherapy improved pathologic complete response (pCR) and event-free survival (EFS), findings from the AEGEAN study have shown.

In the treatment of women with polycystic ovary syndrome (PCOS), adding myoinositol to metformin provides further benefits for improving the regularity of menstrual cycle, with subsequent gains in quality of life, according to a study.

Patients with nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation appear to experience similar survival outcomes with either frontline osimertinib therapy or sequential treatment approach of gefitinib followed by osimertinib, although upfront osimertinib leads to a significant reduction in the risk of brain progression, as shown in the results of the APPLE trial presented at ELCC 2023.

Combination treatment with eftilagimod alpha plus pembrolizumab has shown promising signal of activity against metastatic nonsmall cell lung cancer (NSCLC) in patients resistant to PD-1/PD-L1 inhibitors, as shown in the updated results of the phase II TACTI-002 study.

Combination treatment with pioglitazone plus a sodium-glucose co-transporter 2 (SGLT2) inhibitor helps reduce the risk of developing major adverse cardiovascular events (MACE) and heart failure in individuals with type 2 diabetes mellitus (T2DM) who have no history of cardiovascular disease (CV), as reported in a study.

Not enough children in Singapore are getting vaccinated against influenza, whereas the number of those who are receiving pneumococcal shots has steadily increased over time.

Treatment with pazopanib combined with chemotherapy leads to better overall response rate (ORR) in patients with recurrent or persistent ovarian cancer but falls short of improving survival, reveals a study. In addition, the combination therapy contributes to an increase in several adverse events (AEs).